home / stock / lexxw / lexxw news

LEXXW News and Press, Lexaria Bioscience Corp. Warrant From 07/27/22

Stock Information
Company Name: Lexaria Bioscience Corp. Warrant
Stock Symbol: LEXXW
Market: NASDAQ
Website: lexariabioscience.com
Menu
LEXXW LEXXW Quote LEXXW Short LEXXW News LEXXW Articles LEXXW Message Board
Get LEXXW Alerts

News, Short Squeeze, Breakout and More Instantly...
LEXXW - Lexarias DehydraTECH-CBD Hypertension Study HYPER-H21-4 Dosing Complete with No Serious Adverse Events

(TheNewswire) Kelowna, British Columbia – TheNewswire - July 27, 2022 – Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms is pleased to announce th...
LEXXW - InvestorNewsBreaks - Lexaria Bioscience Corp.'s (NASDAQ: LEXX) Licensee Launches Ko Brand in Preparation to Deploy DehydraTECH CBD Products in Japan

Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug delivery platforms, today announced that its exclusive* Japanese licensee, Premier Wellness Science Co. Ltd., officially launched the first generation of its new cannabidiol (“CBD”) products under the brand ...

LEXXW - Lexaria's Licensee Premier Wellness Science Co., Ltd. Launches New Brand in Preparation to Deploy DehydraTECH CBD Products in Japan

(TheNewswire) Kelowna, British Columbia – TheNewswire - July 26, 2022 – Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms is pleased to announce th...

LEXXW - Lexaria To Receive Third Patent Granted in Japan; Submits FDA Filing

(TheNewswire) Kelowna, British Columbia – TheNewswire - July 14, 2022 – Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms is please...
LEXXW - InvestorNewsBreaks - Lexaria Bioscience Corp. (NASDAQ: LEXX) Nearing Start Date for Its Human Nicotine Study

Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug delivery platforms, today announced the pending start of its upcoming human nicotine study NIC-H22-1. Through the study, Lexaria expects to evidence that processing purified nicotine with its patented drug delivery techno...

LEXXW - Lexarias Human Nicotine Study Nearing Start Date

(TheNewswire) Lexaria is targeting the oral nicotine pouch category, one of the fastest growing segments of the nicotine industry. Kelowna, British Columbia – TheNewswire - July 13, 2022 – Lexaria Bioscience Corp. (Nasdaq:LEXX) (Na...

LEXXW - InvestorNewsBreaks - Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Global Expansion of DehydraTECH Licensee

Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug delivery platforms, today announced that its DehydraTECH licensee Boldt Runners Corporation, owners of the Cannadips brand, has expanded manufacturing agreements to include Europe, Japan and South Africa. “We are d...
LEXXW - Cannadips is Expanding Internationally, Leveraging Lexaria,s DehydraTECH

(TheNewswire) Kelowna, British Columbia – TheNewswire - July 7, 2022 – Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms is pleased to ...

LEXXW - InvestorNewsBreaks - Lexaria Bioscience Corp. (NASDAQ: LEXX) Enters Strategic Manufacturing, License Agreements with BevNology

Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug delivery platforms, today announced the signing of two agreements with Atlanta-based BevNology LLC. According to the update, the first manufacturing operating agreement expands production capabilities for Lexaria’s...

LEXXW - Lexaria Signs Manufacturing and License Agreements with BevNology

(TheNewswire) Expands DehydraTECH™ B2B manufacturing capabilities to support Lexaria’s growing corporate customer base Lexaria to also receive royalty revenue from DehydraTECH product sales through BevNology’s commercial license rig...
Previous 10 Next 10